American Century Companies Inc. Decreases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

American Century Companies Inc. decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 10.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,773,562 shares of the biotechnology company's stock after selling 436,091 shares during the quarter. American Century Companies Inc. owned 1.60% of ADMA Biologics worth $64,717,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Natixis Advisors LLC bought a new position in ADMA Biologics in the 3rd quarter valued at $345,000. Mutual of America Capital Management LLC purchased a new stake in shares of ADMA Biologics during the third quarter valued at $701,000. Intech Investment Management LLC bought a new position in shares of ADMA Biologics in the third quarter worth about $1,242,000. Charles Schwab Investment Management Inc. increased its stake in ADMA Biologics by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company's stock worth $48,007,000 after buying an additional 249,412 shares during the period. Finally, Citigroup Inc. lifted its holdings in ADMA Biologics by 251.7% during the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 0.1 %

Shares of ADMA stock traded down $0.02 during mid-day trading on Friday, hitting $20.26. The stock had a trading volume of 2,360,170 shares, compared to its average volume of 3,517,452. The firm has a market capitalization of $4.79 billion, a P/E ratio of 72.36 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64. The firm's 50-day moving average is $17.13 and its two-hundred day moving average is $18.15.

Remove Ads

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.